HomepageMedicineFDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes Medicine FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes admin Posted on February 18, 2025 Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostArvind SmartSpaces sign ₹600-cr real estate deal in Ahmedabad Next PostXi Jinping's educational philosophy now in four new languages You Might Also Like Medicine FDA Approves Vanda Pharmaceuticals' Fanapt to Treat Adults with Bipolar I Disorder admin April 4, 2024 Medicine Evolution Optiks Receives FDA 510(k) Clearance for LFR-260 as the First Light Field Powered Subjective Tele-Fractor admin June 8, 2024 Medicine FDA Clears Positrigo’s NeuroLF Brain PET System for the Diagnosis of Multiple Brain Disorders admin July 18, 2024 Medicine FDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia admin September 28, 2024
Medicine FDA Approves Vanda Pharmaceuticals' Fanapt to Treat Adults with Bipolar I Disorder admin April 4, 2024
Medicine Evolution Optiks Receives FDA 510(k) Clearance for LFR-260 as the First Light Field Powered Subjective Tele-Fractor admin June 8, 2024
Medicine FDA Clears Positrigo’s NeuroLF Brain PET System for the Diagnosis of Multiple Brain Disorders admin July 18, 2024